Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE ‐ JP Trial
Authors:
- Koutaro YokoteKYKoutaro Yokote
- Toshimasa YamauchiTYToshimasa Yamauchi
- Yasushi FukushimaYFYasushi Fukushima
- Yoji TakatsukaYTYoji Takatsuka
- Marie KatoMKMarie Kato
- Shijia YanSYShijia Yan
- Takayoshi InoueTITakayoshi Inoue
- Luiza BorowskaLBLuiza Borowska
- Martina BrueckmannMBMartina Brueckmann
- Wataru OgawaWOWataru Ogawa
Open Access
- 31 May 2026
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 6595-6606
Abstract
Aims: There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the SYNCHRONIZE‐JP trial evaluating survodutide in Japanese adults with obesity disease ( ClinicalTrials.gov : NCT06176365). Materials and Methods: SYNCHRONIZE‐JP is a 76‐week, randomised, double‐blind, parallel‐group, multi‐centre, phase 3 clinical trial. Eligible participants were aged ≥ 18 years, with BMI ≥ 35 kg/m 2 with ≥ 1 obesity complication or BMI ≥ 27 kg/m 2 with ≥ 2 obesity complications, ≥ 1 self‐reported unsuccessful dietary effort to lose body weight and ≥ 1 obesity complication required to be type 2 diabetes (T2D; capped at 30% enrolment), hypertension or dyslipidaemia. Participants were randomised 1:1:1 to receive once‐weekly survodutide 3.6 or 6.0 mg, or placebo, accompanied by a reduced‐calorie diet and increased physical activity. The primary endpoints are percentage change in body weight and achievement of body weight reduction ≥ 5% from baseline to Week 76. A subset of participants will be assessed for additional endpoints of liver fat content and body composition. Results: Of 274 enrolled participants, 24.1% had T2D. The mean age was 53.1 years; 47.8% were female, and mean BMI was 33.2 kg/m 2 . The most frequent complications were dyslipidaemia (81.4%), hypertension (72.6%), hyperuricaemia (30.3%) and metabolic dysfunction‐associated steatotic liver disease (26.6%). Conclusions: The results of SYNCHRONIZE‐JP will provide Japan‐specific efficacy, safety and tolerability data for survodutide and inform its potential role in the management of obesity disease.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 36 references indexed in Scilit:
- Development and validation of an eating behavior patient‐reported outcome measure in people living with obesity or overweightObesity, 2025
- Sarcopenic obesity in the Asia-Pacific region: Epidemiology, risk factors, and managementOsteoporosis and Sarcopenia, 2025
- Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)Obesity, 2024
- Survodutide for the Treatment of ObesityJACC: Heart Failure, 2024
- Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment ComparisonAdvances in Therapy, 2024
- Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trialDiabetologia, 2023
- Relevance of body composition in phenotyping the obesitiesReviews in Endocrine and Metabolic Disorders, 2023
- BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacyMolecular Metabolism, 2022
- A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage onMetabolism, 2022
- Epidemiological Features of NAFLD From 1999 to 2018 in ChinaHepatology, 2020